Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Research & Development (2016 - 2026)

Akebia Therapeutics has reported Research & Development over the past 10 years, most recently at $1.0 million for Q4 2025.

  • Quarterly Research & Development fell 91.52% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.7 million through Dec 2025, down 2.5% year-over-year, with the annual reading at $62.4 million for FY2025, 65.62% up from the prior year.
  • Research & Development was $1.0 million for Q4 2025 at Akebia Therapeutics, down from $14.9 million in the prior quarter.
  • Over five years, Research & Development peaked at $43.8 million in Q1 2022 and troughed at $1.0 million in Q4 2025.
  • The 5-year median for Research & Development is $14.1 million (2023), against an average of $19.1 million.
  • Year-over-year, Research & Development plummeted 94.32% in 2021 and then soared 767.57% in 2022.
  • A 5-year view of Research & Development shows it stood at $29.6 million in 2021, then increased by 8.6% to $32.1 million in 2022, then tumbled by 69.27% to $9.9 million in 2023, then rose by 19.47% to $11.8 million in 2024, then tumbled by 91.52% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Research & Development are $1.0 million (Q4 2025), $14.9 million (Q3 2025), and $11.0 million (Q2 2025).